These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25720063)

  • 21. Free sphingoid bases in tissues from patients with type C Niemann-Pick disease and other lysosomal storage disorders.
    Rodriguez-Lafrasse C; Rousson R; Pentchev PG; Louisot P; Vanier MT
    Biochim Biophys Acta; 1994 May; 1226(2):138-44. PubMed ID: 8204660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetics of sphingolipid hydrolases and sphingolipid storage diseases.
    Schuchman EH; Simonaro CM
    Handb Exp Pharmacol; 2013; (215):3-32. PubMed ID: 23579447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disorders.
    Wang A; Chen C; Mei C; Liu S; Xiang C; Fang W; Zhang F; Xu Y; Chen S; Zhang Q; Bai X; Lin A; Neculai D; Xia B; Ye C; Zou J; Liang T; Feng XH; Li X; Shen C; Xu P
    Nat Cell Biol; 2024 Feb; 26(2):219-234. PubMed ID: 38253667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on a sphingolipid activator protein (SAP-2) in fibroblasts from patients with lysosomal storage diseases, including Niemann-Pick disease Type C.
    Fujibayashi S; Wenger DA
    Clin Chim Acta; 1985 Mar; 146(2-3):147-56. PubMed ID: 3921288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substrate reduction therapy.
    Platt FM; Jeyakumar M
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of immune abnormalities in lysosomal storage disorders.
    Rigante D; Cipolla C; Basile U; Gulli F; Savastano MC
    Immunol Lett; 2017 Aug; 188():79-85. PubMed ID: 28687233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.
    Kirkegaard T; Gray J; Priestman DA; Wallom KL; Atkins J; Olsen OD; Klein A; Drndarski S; Petersen NH; Ingemann L; Smith DA; Morris L; Bornæs C; Jørgensen SH; Williams I; Hinsby A; Arenz C; Begley D; Jäättelä M; Platt FM
    Sci Transl Med; 2016 Sep; 8(355):355ra118. PubMed ID: 27605553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid storage disease: Part II. Ultrastructural pathology of lipid storage cells in sphingolipidoses.
    Takahashi K; Naito M
    Acta Pathol Jpn; 1985 Mar; 35(2):385-408. PubMed ID: 2992227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. My journey into the world of sphingolipids and sphingolipidoses.
    Sandhoff K
    Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(10):554-82. PubMed ID: 23229750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Newborn screening for lysosomal storage disorders.
    Nakamura K; Hattori K; Endo F
    Am J Med Genet C Semin Med Genet; 2011 Feb; 157C(1):63-71. PubMed ID: 21312327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lyso-glycosphingolipids: presence and consequences.
    van Eijk M; Ferraz MJ; Boot RG; Aerts JMFG
    Essays Biochem; 2020 Sep; 64(3):565-578. PubMed ID: 32808655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of the type I interferon response in neurological forms of Gaucher disease.
    Vitner EB; Farfel-Becker T; Ferreira NS; Leshkowitz D; Sharma P; Lang KS; Futerman AH
    J Neuroinflammation; 2016 May; 13(1):104. PubMed ID: 27175482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary Mitochondrial Dysfunction as a Cause of Neurodegenerative Dysfunction in Lysosomal Storage Diseases and an Overview of Potential Therapies.
    Stepien KM; Cufflin N; Donald A; Jones S; Church H; Hargreaves IP
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biochemical pathophysiology of ataxia in the sphingolipidoses.
    Philippart M
    Adv Neurol; 1978; 21():131-49. PubMed ID: 104554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysosomal Ca(2+) homeostasis: role in pathogenesis of lysosomal storage diseases.
    Lloyd-Evans E; Platt FM
    Cell Calcium; 2011 Aug; 50(2):200-5. PubMed ID: 21724254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic and cellular bases of sphingolipidoses.
    Sandhoff K
    Biochem Soc Trans; 2013 Dec; 41(6):1562-8. PubMed ID: 24256255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zebra-Sphinx: Modeling Sphingolipidoses in Zebrafish.
    Mignani L; Guerra J; Corli M; Capoferri D; Presta M
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of morphologic assessment of bone marrow biopsy in diagnosis of lysosomal storage disorders.
    Nishith N; Siddiqui SH; R Raja SK; Agrawal N; Phadke S; Sharma S
    Indian J Pathol Microbiol; 2023; 66(1):91-95. PubMed ID: 36656217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylamine accumulation in cultured cells as a measure of the aqueous storage compartment in the laboratory diagnosis of genetic lysosomal diseases.
    Kopitz J; Harzer K; Kohlschütter A; Zöller B; Blenck N; Cantz M
    Am J Med Genet; 1996 May; 63(1):198-202. PubMed ID: 8723110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the biochemistry and genetics of sphingolipidoses.
    Ozkara HA
    Brain Dev; 2004 Dec; 26(8):497-505. PubMed ID: 15533650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.